Navigation Links
Study: Many cancer survivors smoke years after diagnosis
Date:8/5/2014

finding that the researchers say has not been previously reported.

"Effective cessation treatment for cancer survivors exists," write the authors, "but future population-based studies examining the importance of psychosocial variables, and their relationships to other health-related variables in predicting current smoking or motivation to quit, will further contribute to enhancing cessation strategies for all survivors who smoke."

The authors conclude that "Those who smoke heavily long after their diagnosis may require more intense treatment addressing specific psychosocial characteristics such as perceptions of risk, beliefs of fatalism, etc. that may influence motivation to quit."


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. Study: Insomnia takes toll on tinnitus patients
3. Study: No link between depression, nasal obstruction
4. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
5. Study: Kids Who Sleep in Parents Bed Less Likely to Be Overweight
6. OHSU study: Misdiagnosis of MS is costing health system millions per year
7. UW study: Sleep apnea associated with higher mortality from cancer
8. Study: Heart damage after chemo linked to stress in cardiac cells
9. STeleR study: Telerehab improves functioning after stroke
10. Study: Willingness to be screened for dementia varies by age but not by sex, race or income
11. Study: 21 percent of newly admitted nursing home residents sustain a fall during their stay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... the development of it’s new program “Designing Secure Healthcare Systems” This three-day, ... and technology leaders from healthcare organizations with access to the tactics, techniques and ...
(Date:8/3/2015)... ... ... A July 13 article from The Daily Mail titled "Jab That ... Can Last 'For Five Weeks'" discusses the use of stem cells to help ... harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal cells ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... WASHINGTON, Oct. 8 The U.S. Department of,Labor ... 700,jobless workers with partial premium payments for health ... nearly 700 North Carolinians who are,looking for work ... afford health insurance for themselves and their families," ...
... YORK, Oct. 8 Weight Watchers,International, Inc. (NYSE: ... Steven,C. McCormick to serve as its President, North ... with extensive consumer product,operations and general management experience, ... its North American products,publishing and licensing businesses and ...
... their levels correlate with cardiovascular trouble , , WEDNESDAY, Oct. ... activity of genes in white blood cells might someday ... of chest pain, researchers report. , The finding is ... the first issue of a new American Heart Association ...
... Sinobiomed Inc.,("Sinobiomed", or "the Company") (OTC Bulletin ... of Directors voted on October 2, 2008 to ... Officer under a,Corporate Consulting Services Agreement to be ... Choong has been appointed to the Company,s audit,committee. ...
... (OTC Bulletin Board:,VYTC) today announced that effective October ... as an independent scientific consultant to Vyta Corp.,Dr. ... Development at,BIOAGRA, LLC, a joint venture, equally owned ... 15, 2008, Vyta Corp announced its filing of,foreclosure ...
... 8 Dr. Jane Hightower -- widely,acknowledged as the ... who regularly consume certain types of fish -- today,released ... inform and protect,the public from the risks of mercury ... Hightower has released a new book, Diagnosis:,Mercury: Money, Politics, ...
Cached Medicine News:Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Blood Cell Genes May Signal Heart Disease 2Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:New Evidence Highlights Dangers of Mercury Toxicity in Fish 2
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
(Date:8/3/2015)... Israel , August 3, 2015 ... received the statistical analysis of results from a study which ... BVX-005 phase II trial which took place in 2012, provided ... exist at the time of the study- in particular the ... epidemic in the United States in ...
(Date:8/3/2015)... 3, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... an exclusive licensing agreement to develop and commercialize multiple ... Limited, a holding company for premier antibody development and ... Under the terms of the agreement, Sorrento ... for the North American, European and Japanese market. Each ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4
... YORK, April 9, 2008 Intra-Cellular Therapies, ... ongoing development,programs for ITI-007, the Company,s first-in-class ... and ITI-722,a low-dose formulation of ITI-007, which ... respectively. These new data demonstrate,ITI-007 has preclinical ...
... ... - Preliminary Phase I/II results to be presented in June at 2008 ... ... ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has advanced CR011-vcMMAE, ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 2Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 3CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
Inquire...
Richardson Retractor...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
... implant is an expanded porous polytetrafluoroethylene,material ... repair of the soft tissues of ... in sheets and shaped geometries with ... implant strands are packaged with and,without ...
Medicine Products: